LU90999I2 - Escitalopram et ses sels pharmaceutiquement acceptables (cipralex) - Google Patents

Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)

Info

Publication number
LU90999I2
LU90999I2 LU90999C LU90999C LU90999I2 LU 90999 I2 LU90999 I2 LU 90999I2 LU 90999 C LU90999 C LU 90999C LU 90999 C LU90999 C LU 90999C LU 90999 I2 LU90999 I2 LU 90999I2
Authority
LU
Luxembourg
Prior art keywords
cipralex
escitalopram
pharmaceutically acceptable
acceptable salts
well
Prior art date
Application number
LU90999C
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10638616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90999(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of LU90999I2 publication Critical patent/LU90999I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Compounds (AREA)
LU90999C 1988-06-14 2003-01-15 Escitalopram et ses sels pharmaceutiquement acceptables (cipralex) LU90999I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888814057A GB8814057D0 (en) 1988-06-14 1988-06-14 New enantiomers & their isolation

Publications (1)

Publication Number Publication Date
LU90999I2 true LU90999I2 (fr) 2003-03-17

Family

ID=10638616

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90999C LU90999I2 (fr) 1988-06-14 2003-01-15 Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)

Country Status (24)

Country Link
US (2) US4943590A (fr)
EP (1) EP0347066B1 (fr)
JP (2) JP3044253B2 (fr)
AT (1) ATE119896T1 (fr)
AU (1) AU623144B2 (fr)
CA (2) CA1339452C (fr)
CY (2) CY2081B1 (fr)
DE (2) DE10399030I2 (fr)
DK (2) DK259989A (fr)
ES (1) ES2068891T4 (fr)
FI (4) FI98627C (fr)
GB (1) GB8814057D0 (fr)
GR (1) GR3015889T3 (fr)
HK (1) HK139596A (fr)
HU (1) HU211460A9 (fr)
IE (1) IE65734B1 (fr)
IL (1) IL90465A (fr)
LU (1) LU90999I2 (fr)
MX (1) MX9203346A (fr)
NL (1) NL300155I2 (fr)
NO (2) NO172892C (fr)
NZ (1) NZ229426A (fr)
PT (1) PT90845B (fr)
ZA (1) ZA894476B (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
WO1992020641A1 (fr) * 1991-05-20 1992-11-26 Chisso Corporation Derive optiquement actif de l'acide trifluorolactique et composition a base de cristaux liquides
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
DE4439836C1 (de) * 1994-11-08 1996-06-05 Hoechst Ag cis-4-(2,2,3,3-Tetrafluorpropoxy)-zimtsäurenitril und trans-4-(2,2,3,3-Tetrafluorpropoxy)- zimtsäurenitril und ein Verfahren zu ihrer Herstellung
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
IL143422A0 (en) 1998-12-23 2002-04-21 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
HRP20020344B1 (hr) 1999-10-25 2010-10-31 H. Lundbeck A/S Način priprave citaloprama
GB2360281B (en) 1999-10-25 2002-01-16 Lundbeck & Co As H Method for the preparation of citalopram
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
HUP0203635A3 (en) 1999-12-28 2005-02-28 Lundbeck & Co As H Method for the preparation of citalopram
CN1195749C (zh) * 2000-01-14 2005-04-06 H.隆德贝克有限公司 制备5－氰基2－苯并[c]呋喃酮的方法
NL1017415C1 (nl) 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
NL1017417C1 (nl) 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
CN1427835A (zh) * 2000-03-13 2003-07-02 H·隆德贝克有限公司 5－取代的1－(4－氟苯基)－1,3－二氢异苯并呋喃的分步烷基化
KR20020080481A (ko) 2000-03-13 2002-10-23 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
TR200202155T2 (tr) 2000-03-14 2002-12-23 H. Lundbeck A/S Sitalopramin preparasyon metodu
DE10190485T1 (de) * 2000-03-16 2002-03-21 Lundbeck & Co As H Verfahren zur Herstellung von 5-Cyano-1-(4-fluorphenyl)-1,3-dihydroisobenzofuranen
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EA008372B1 (ru) * 2000-07-07 2007-04-27 Х.Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
EA008373B1 (ru) * 2000-07-07 2007-04-27 Х. Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EP1303265B1 (fr) * 2000-07-20 2007-07-11 Lauras AS Utilisation d'inhibiteurs de cox-2 en tant qu'immunostimulants dans le traitement du vih ou du sida
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
CA2354877C (fr) 2000-08-18 2006-05-02 H. Lundbeck A/S Methode de preparation de citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
JP2003519121A (ja) * 2000-12-28 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット 純粋なシタロプラムの製造方法
EP1355897A1 (fr) 2001-01-30 2003-10-29 Orion Corporation Fermion Procede de preparation de 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
WO2002087566A1 (fr) * 2001-05-01 2002-11-07 H. Lundbeck A/S Utilisation d'escitalopram pur enantiomere
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IL159326A0 (en) * 2001-07-31 2004-06-01 Lundbeck & Co As H Crystalline composition containing escitalopram
DK1281707T3 (da) * 2001-08-02 2005-05-02 Infosint Sa Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
US7148364B2 (en) * 2002-01-07 2006-12-12 Sun Pharmaceutical Industries Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
US7192939B2 (en) * 2002-01-30 2007-03-20 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
EP1346989A1 (fr) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Procede ameliore de preparation de citalopram et de bromhydrate de citalopram
CA2381341A1 (fr) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Methode de preparation et intermediaires connexes pour la synthese de l'escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
AR040970A1 (es) * 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003287919B2 (en) * 2002-12-23 2009-11-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
EP2363389A1 (fr) 2002-12-23 2011-09-07 H. Lundbeck A/S Procédé de preparation de citalopram diol racémique et/ou S- ou R-citalopram diols ainsi qu'utilisation de tels diols pour la preparation de citalopram racémique, R-citalopram et/ou S-citralopram
EA009061B1 (ru) * 2002-12-23 2007-10-26 Х. Лундбекк А/С Способ получения рацемического циталопрамдиола и/или s- или r- циталопрамдиолов и способ получения рацемического циталопрама, r-циталопрама и /или s-циталопрама
EP1611118A2 (fr) * 2003-03-21 2006-01-04 H. Lundbeck A/S Intermediaires servant a la preparation du citalopram et de l'escitalopram
WO2004085416A1 (fr) * 2003-03-24 2004-10-07 Hetero Drugs Limited Formes cristallines d'oxalate de (s)-citaloprame
US7019153B2 (en) 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
ES2228274B1 (es) * 2003-09-24 2006-06-01 Astur Pharma, S.A. Sintesis quimioenzimatica de (+)-citalopram y (-)-citalopram.
PT1506963E (pt) * 2003-10-28 2005-08-31 Adorkem Technology Spa Processo para a preparacao de citalopram
US20050101666A1 (en) * 2003-11-07 2005-05-12 H. Lundbeck A/S Method of treating premenstrual dysphoric disorder with escitalopram
WO2005047274A1 (fr) * 2003-11-12 2005-05-26 Dr. Reddy's Laboratories, Inc. Preparation d'escitaloprame
US20050107466A1 (en) * 2003-11-17 2005-05-19 H. Lundbeck A/S Method of treating or reducing suicidal thoughts with escitalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005049596A1 (fr) * 2003-11-20 2005-06-02 Natco Pharma Limited Procede de preparation d'escitalopram de haute purete
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
WO2005084643A1 (fr) * 2004-03-05 2005-09-15 H. Lundbeck A/S Composition cristalline contenant de l'oxalate d'escitalopram
ITMI20040717A1 (it) 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
WO2006006071A1 (fr) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution de compose azapolycyclique fusionne aryle
ES2285972T1 (es) 2004-08-23 2007-12-01 Sun Pharmaceutical Industries Limited Procedimiento de fabricacion de citalopram y enantiomeros.
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
WO2006025071A1 (fr) * 2004-09-02 2006-03-09 Natco Pharma Limited Procédé de synthèse de l'escitalopram
ITMI20041872A1 (it) * 2004-10-01 2005-01-01 Adorkem Technology Spa Processo per la preparazione di citalopram e di scitalopram
EP1877394A1 (fr) * 2005-04-04 2008-01-16 Jubilant Organosys Limited Processus de preparation d'escitalopram ou de ses sels d'addition acides
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
WO2006116165A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives de chromane et de chromene, et leurs utilisations
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
WO2006123243A2 (fr) * 2005-05-20 2006-11-23 Aurobindo Pharma Limited Formes galeniques pharmaceutiques d'un antidepresseur
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI347942B (en) 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EP1987016A1 (fr) * 2005-07-27 2008-11-05 Aurobindo Pharma Limited Procédé amélioré pour la préparation d'escitalopram
JP2009511607A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
JP2009515840A (ja) * 2005-11-14 2009-04-16 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造方法
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
EP1998773A2 (fr) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
CA2672925A1 (fr) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram et composition pharmaceutique solide comprenant cette structure
US20100003313A1 (en) 2006-10-27 2010-01-07 Hisamitsu Pharmaceutical Co.,Inc. Adhesive skin patch
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
WO2008104880A2 (fr) * 2007-03-01 2008-09-04 Aurobindo Pharma Limited Formes posologiques solides stables d'un antidépresseur
US7566793B2 (en) * 2007-04-23 2009-07-28 Synthon Bv Process for resolving citalopram
JP2010527345A (ja) 2007-05-18 2010-08-12 シプラ・リミテッド エスシタロプラムの調製方法
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (fr) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Procédé de préparation d'escitalopram
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
US8022232B2 (en) 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
FI121570B (fi) * 2007-09-11 2011-01-14 Lundbeck & Co As H Menetelmä essitalopraamin valmistamiseksi
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
CN101538257B (zh) * 2008-03-21 2012-10-17 浙江华海药业股份有限公司 一种制备西酞普兰和s-西酞普兰的方法
CN101265215B (zh) * 2008-04-18 2011-03-16 浙江奥托康制药集团股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
EP2116231A1 (fr) 2008-05-07 2009-11-11 Hexal Ag Granulé comprenant de l'oxalate d'escitalopram
WO2009147687A2 (fr) * 2008-06-03 2009-12-10 Shodhana Laboratories Limited Méthode améliorée de séparation de composés énantiomériquement purs
US20110092719A1 (en) * 2008-06-16 2011-04-21 Shodhana Laboratories Limited Preparation of Escitalopram, Its Salts and Intermediates
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20100249438A1 (en) * 2009-03-30 2010-09-30 Vijaya Bhaskar Bolugoddu Preparation of escitalopram
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN102190600B (zh) * 2010-03-13 2015-04-15 浙江华海药业股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
CN102757414B (zh) * 2011-04-25 2014-02-19 齐鲁制药有限公司 艾司西酞普兰草酸盐的制备方法
WO2013100870A1 (fr) 2011-12-02 2013-07-04 Mahmut Bilgic Nouvelles compositions antipsychotiques
WO2013081567A1 (fr) 2011-12-02 2013-06-06 Mahmut Bilgic Formulations antipsychotiques effervescentes
ITMI20120105A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Soluzione acquosa di escitalopram ossalato e relativo utilizzo
ITMI20120448A1 (it) 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
CN104119248A (zh) * 2014-08-08 2014-10-29 广东东阳光药业有限公司 S-西酞普兰的制备方法
US10287240B2 (en) * 2014-11-14 2019-05-14 Zhejiang Hushai Pharmaceuticals Co., Ltd. Method for resolution of citalopram intermediate 5-cyano diol
CN107848958B (zh) 2015-06-09 2020-10-23 浙江华海药业股份有限公司 一种西酞普兰二醇中间体的制备方法
CN107311968A (zh) * 2016-03-31 2017-11-03 广州市恒诺康医药科技有限公司 西酞普兰帕莫酸盐和其结晶形态及其制备方法和用途
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
CN111194312A (zh) 2017-10-09 2020-05-22 提瓦制药工业公司 依地普仑的新盐和固态形式
CN111217777A (zh) 2018-11-26 2020-06-02 上海奥博生物医药技术有限公司 一种高纯度艾司西酞普兰双羟萘酸盐新的制备工艺
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
KR102441089B1 (ko) 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method

Also Published As

Publication number Publication date
FI892823L (fi) 1989-12-15
DE10399030I2 (de) 2004-08-12
DK259989D0 (da) 1989-05-29
EP0347066A1 (fr) 1989-12-20
DE10399030I1 (de) 2004-01-08
ATE119896T1 (de) 1995-04-15
FI20041359A7 (fi) 2004-10-20
FI20041359L (fi) 2004-10-20
EP0347066B1 (fr) 1995-03-15
ZA894476B (en) 1990-04-25
GR3015889T3 (en) 1995-07-31
DK11593A (da) 1993-02-01
NO2002014I2 (no) 2005-03-21
NO892447D0 (no) 1989-06-13
FI113762B (fi) 2004-06-15
AU623144C (en) 1990-01-04
IE65734B1 (en) 1995-11-15
JPH11292867A (ja) 1999-10-26
FI98627C (fi) 1997-07-25
HK139596A (en) 1996-08-02
ES2068891T3 (es) 1995-05-01
FI941829A0 (fi) 1994-04-20
MX9203346A (es) 1992-08-31
CA1339568C (fr) 1997-12-02
NL300155I1 (nl) 2004-09-01
NO172892B (no) 1993-06-14
NO172892C (no) 1993-09-22
DK259989A (da) 1989-12-15
CY2081B1 (en) 1998-10-16
NO892447L (no) 1989-12-15
DK11593D0 (da) 1993-02-01
FI20000507L (fi) 2000-03-06
CY2007004I2 (el) 2009-11-04
JP3038204B2 (ja) 2000-05-08
AU3629589A (en) 1990-01-04
FI941829L (fi) 1994-04-20
FI91527B (fi) 1994-03-31
HU211460A9 (en) 1995-11-28
CY2007004I1 (el) 2009-11-04
FI892823A0 (fi) 1989-06-08
GB8814057D0 (en) 1988-07-20
CA1339452C (fr) 1997-09-09
IL90465A (en) 1995-01-24
NL300155I2 (nl) 2005-09-01
DE68921672D1 (de) 1995-04-20
IE891859L (en) 1989-12-14
NZ229426A (en) 1990-12-21
AU623144B2 (en) 1992-05-07
PT90845B (pt) 1994-11-30
USRE34712E (en) 1994-08-30
US4943590A (en) 1990-07-24
JPH0236177A (ja) 1990-02-06
JP3044253B2 (ja) 2000-05-22
DK170280B1 (da) 1995-07-24
ES2068891T4 (es) 2012-02-07
FI20000507A7 (fi) 2000-03-06
DE68921672T2 (de) 1995-07-27
PT90845A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
LU90999I2 (fr) Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
DE69201959D1 (de) Verfahren zur Herstellung von 6,12-Dihydro-6-hydroxy-cannabidiol und dessen Anwendung zur Herstellung von trans-delta-9-Tetrahydrocannabinol.
DE69738154D1 (de) Optische auflösung von methylphenidat mittels 0,0'-bisaroyl-weinsäuren
EA200000057A1 (ru) (+)-норцисаприд, пригодный для лечения нарушений, опосредованных 5-нт3 и 5-нт4 (рецепторами)
DE69207429D1 (de) Verfahren zur herstellung von substituierten piperidinen
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
IT8922075A0 (it) Processo per l'inversione stereochimica di (2s,3s)-2-ammino-3-fenil-1 ,3-propandioli nei corrispondenti enantiomeri (2r,3r)
IT1231751B (it) Procedimento per la produzione di r(+) amminocarnitina e s(-) amminocarnitina
ATE79116T1 (de) Aminosaeureester, verfahren zu ihrer herstellung und ihre verwendung.
DE69707603D1 (de) Verfahren zur Herstellung von N2-Arylsulfonyl-L-Argininamiden
ATE62237T1 (de) Chroman- und thiochroman-4-essigsaeuren, verwendbar bei der behandlung von zuckerkrankheitskomplikationen.
IT8621359A1 (it) Processo per la sintesi di acidi carbossilici
DE69200389D1 (de) Verfahren zur Herstellung von Enantiomeren von 3-Aminchromanderivaten.
MX9803646A (es) Un procedimiento para producir derivados de acido 3-fenil-1-metilendioxifenil-indano-2-carboxilico.
ATE421953T1 (de) Verfahren zur racemisierung von 1-benzyl-4-(4- fluorophenyl)-3-hydroxymethyl-1,2,3,6- tetrahydropyridin und dessen verwendung in der synthese von paroxetin